When Your PSA Comes Back:

Biochemical recurrence after radical prostatectomy: Where do we stand to? | Prostate Cancer and Prostatic Diseases

Understanding Biochemical Recurrence After Prostate Surgery

IPCSG Educational Newsletter — Research Digest Series

June 2026 • Prepared for the Informed Prostate Cancer Support Group

Bottom Line Up Front (BLUF) 

Rising PSA after a radical prostatectomy — called biochemical recurrence, or BCR — affects up to half of all men within a decade of surgery, but it does not mean the cancer has spread or that the situation is hopeless. The standard treatment, salvage radiotherapy directed at the surgical bed, cures many men, especially when given early at low PSA levels. New data confirm that adding hormone therapy, expanding radiation to the pelvis, and in some high-risk cases using next-generation androgen receptor blockers, can all improve outcomes further. PSMA-PET imaging is a powerful new tool, but at the very low PSA levels at which modern salvage treatment typically begins, it often shows nothing — and a negative scan should not delay starting radiation. This article walks through what the latest trials and guidelines tell us, in plain language.

What Is Biochemical Recurrence?

After a radical prostatectomy (RP) — surgical removal of the prostate — the PSA level should fall to essentially zero and remain there. If PSA rises again on two consecutive measurements to above 0.2 ng/mL, doctors call that biochemical recurrence (BCR). Some researchers argue that a threshold of 0.4 ng/mL is actually a better predictor of cancer spreading to distant sites, but the 0.2 ng/mL standard remains the most widely used clinical definition.

BCR is not rare. Studies show it occurs in up to 50% of men within 10 years of surgery, with the risk highest in those who had aggressive-grade tumors or cancer that extended beyond the prostate capsule. The key thing to understand is that a rising PSA number alone — with no symptoms and no visible disease on scans — is the signal we are talking about here. Most men with BCR feel perfectly fine.

The arrival of ultrasensitive PSA tests means doctors are now catching BCR earlier than ever, often before the number reaches 0.2. Salvage treatment today frequently begins when PSA is below 0.5 ng/mL, and sometimes below 0.2 ng/mL. That matters, because every 0.1 ng/mL rise in PSA at the time salvage radiotherapy begins is associated with a roughly 2.4% drop in the chance of staying recurrence-free afterward. Earlier really is better.

Key Terms to Know

BCR (Biochemical Recurrence): PSA rise after surgery, usually defined as >0.2 ng/mL on two measurements.
SRT (Salvage Radiotherapy): Radiation given to treat BCR, usually aimed at the prostate bed where surgery was performed.
PBRT (Prostate Bed Radiotherapy): Radiation targeted specifically to the surgical bed.
WPRT (Whole Pelvis Radiotherapy): Broader radiation field that also covers nearby pelvic lymph nodes.
ADT (Androgen Deprivation Therapy): Hormone therapy that lowers testosterone to starve prostate cancer cells.
PSMA-PET: A highly sensitive nuclear medicine scan that finds prostate cancer cells using a prostate-specific protein as a target.
PSA Doubling Time (PSADT): How quickly PSA is rising. A doubling time under 12 months signals higher-risk disease.
MFS (Metastasis-Free Survival): How long a patient lives without developing visible spread to distant organs or bones.

Who Is at Higher Risk?

Not all BCR is the same. European guidelines formally divide it into low-risk and high-risk categories. High-risk BCR is defined by either a PSA doubling time shorter than 12 months or a Gleason/ISUP grade of 4 or 5 on the original biopsy or surgery specimen. The 2024 joint guidelines from the American Urological Association (AUA), American Society for Radiation Oncology (ASTRO), and the Society of Urologic Oncology (SUO) similarly highlight that a short interval to BCR, high Gleason score, and a fast PSA doubling time all independently predict worse outcomes, including eventual spread and cancer-specific death.

The distinction between low- and high-risk BCR matters because it guides how aggressively to treat. A man with slowly rising PSA, a long doubling time, and favorable original pathology may do well with prostate-bed radiation alone. A man with rapidly rising PSA and high-grade original disease likely benefits from a more intensified approach.

The Role of PSMA-PET Imaging

PSMA-PET scanning has been a genuine revolution in prostate cancer imaging. It can find cancer deposits that conventional CT and bone scans simply miss. Studies show PSMA-PET detects disease in roughly 33–45% of patients whose PSA is below 0.5 ng/mL at the time of scanning, and that rate climbs above 90% when PSA exceeds 2 ng/mL.

Here is the critical practical point: most men today are referred for salvage treatment when their PSA is still very low, often well under 0.5 ng/mL. At those low levels, a majority of PSMA-PET scans come back negative — meaning the scan doesn’t find the problem even though the rising PSA tells us something is happening.

The PRIMORDIUM study confirmed this pattern among 198 men with high-risk BCR and median PSA of 0.35 ng/mL: 55% of PSMA-PET scans were completely negative. Local or regional (pelvic) disease was found in 40% of patients, but distant spread was identified in only 5%. The Canadian PSMAiSRT trial reached similar conclusions — about 44% of scans were negative, and fewer than 3% showed distant metastases.

A UCLA/JNCCN study published in early 2026 reported that a negative PSMA-PET scan at BCR actually identifies a favorable-risk group, with 5-year progression-free survival of about 62% even without treatment — but that salvage radiotherapy still improved those numbers in patients with locally recurrent disease. The bottom line from multiple research teams is the same: a negative PSMA-PET scan at low PSA should not be used as a reason to delay salvage radiotherapy. Early treatment remains the preferred strategy, regardless of what the scan shows.

Patient Perspective: If your doctor tells you the PSMA-PET was negative and suggests waiting, it is entirely appropriate to ask: “Given the trial data showing limited sensitivity at my PSA level, would early salvage radiation still be appropriate for me?” The evidence strongly supports early treatment rather than watchful waiting for the scan to turn positive.

Salvage Radiotherapy: The Standard of Care

Salvage radiotherapy (SRT) directed at the prostate bed is the established standard treatment for BCR after surgery. Three large randomized trials — SPPORT, GETUG-AFU 16, and RADICALS-HD — have shaped current practice, and their findings are highly relevant to patients today.

SPPORT Trial (NRG Oncology/RTOG 0534)

This landmark international trial followed patients for a median of 8.2 years. Men who received whole-pelvis radiotherapy (WPRT) combined with 6 months of ADT had a dramatically better chance of staying free from progression: 87.4% at 5 years, compared with 70.9% for prostate-bed radiation alone. The intensified approach also cut the rate of distant metastases roughly in half (HR 0.52) and reduced prostate cancer–specific deaths by about half (HR 0.51). Crucially, 69% of patients in this trial had PSA values below 0.5 ng/mL at the time of enrollment — meaning these benefits apply at the early treatment stages most relevant today.

GETUG-AFU 16 Trial

French investigators followed patients for more than 10 years (median 122 months) after random assignment to pelvic salvage radiotherapy with or without 6 months of ADT. Adding hormone therapy significantly improved both progression-free survival (HR 0.54) and metastasis-free survival (HR 0.73). All enrolled patients received pelvic irradiation, reinforcing the message that broader radiation plus short-term ADT is a potent combination.

RADICALS-HD Trial

This UK-led trial asked a different question: if we are going to add ADT to salvage radiation, how long should we give it? The comparison was 6 months versus 24 months of ADT. The result: 6 months of ADT on its own did not significantly improve metastasis-free survival compared with radiation alone (HR 0.88, not statistically significant). However, extending ADT to 24 months did produce a significant improvement in metastasis-free survival compared with 6 months (HR 0.77). There is an important caveat: 93–95% of patients in RADICALS-HD received prostate-bed radiation only, without pelvic nodal coverage, unlike the other two trials. The benefit of long-term ADT in RADICALS-HD was also largely confined to patients with PSA above 0.5 ng/mL or those treated in the adjuvant (immediate postoperative) setting, rather than in the salvage setting at low PSA.

Key Randomized Trial Results: Salvage Radiotherapy + Hormone Therapy

Trial	Pelvic Radiation?	ADT Duration	PSA <0.5 at Entry	Key Outcome (MFS)
SPPORT	Yes (WPRT arm)	6 months	69%	HR 0.79 favoring WPRT+ADT
GETUG-AFU 16	Yes (all patients)	6 months	100% (<0.5)	HR 0.73 favoring ADT addition
RADICALS-HD (6mo vs none)	Rarely (5–7%)	6 months	81%	HR 0.89, not significant
RADICALS-HD (24mo vs 6mo)	Rarely (5–7%)	24 months	81%	HR 0.77, significant

What Meta-Analyses Tell Us

Two large meta-analyses — POSEIDON and DADSPORT — pooled individual patient data from multiple trials to get a clearer picture. Neither found an overall survival benefit from adding ADT to salvage radiotherapy, likely because most patients eventually receive additional treatments that muddy the long-term picture. Both meta-analyses did, however, confirm that ADT significantly improves metastasis-free survival, with hazard ratios of 0.79 (POSEIDON) and 0.78 (DADSPORT) — translating to approximately one metastasis or death prevented for every 25 patients treated.

The DADSPORT data also shed light on who benefits most. Men with PSA below 0.2 ng/mL showed little clear benefit from adding ADT. But as PSA rose, the benefit grew: the number of patients needing treatment to prevent one metastasis or death ranged from 21 (for PSA 0.21–0.5 ng/mL) down to just 7 (for PSA above 1 ng/mL). This suggests that the decision to add ADT should be individualized based on PSA level and risk features.

A Major New Development: The EMBARK Trial and Overall Survival

Perhaps the most significant news for BCR patients in 2025 came from the phase 3 EMBARK trial, presented at the European Society for Medical Oncology (ESMO) Annual Congress in Berlin in October 2025 and published simultaneously in the New England Journal of Medicine.

EMBARK enrolled men with high-risk BCR — defined by a PSA doubling time of 9 months or less, and PSA at least 1 ng/mL after surgery. These are patients with aggressive-behaving disease who have not yet developed visible metastases. The trial compared three approaches: enzalutamide (Xtandi) plus leuprolide (standard ADT), enzalutamide alone, or leuprolide alone.

Earlier results had already shown that enzalutamide combinations dramatically improved metastasis-free survival. The 2025 ESMO update delivered the overall survival data that the field had been waiting for. The combination of enzalutamide plus leuprolide reduced the risk of death by more than 40% compared with leuprolide alone — a statistically significant and clinically meaningful improvement. Enzalutamide monotherapy did not show a statistically significant overall survival advantage over leuprolide alone, though it continued to show metastasis-free survival benefit.

The ESMO discussant summarized the significance clearly: enzalutamide plus ADT is now a standard of care in high-risk BCR. Enzalutamide monotherapy remains a reasonable option for patients who wish to preserve sexual function or avoid the worst effects of testosterone suppression, after weighing individual risks and benefits with their doctor.

Important Nuance: EMBARK enrolled patients with high-risk BCR: PSA doubling time ≤9 months and PSA ≥1 ng/mL after surgery. Men with slow-rising PSA or very low PSA values at BCR were not the target population of this trial. The benefits seen in EMBARK apply specifically to higher-risk patients and should not automatically be assumed for everyone with any BCR.

The Question of Who Needs What

Bringing these trials together, a clearer picture is emerging for individualized care:

Low PSA (<0.2 ng/mL), slow doubling time, favorable pathology: Prostate-bed radiation alone (PBRT) is the foundational treatment. The benefit of adding ADT or pelvic radiation is less certain at these very low PSA levels, and some experts favor careful observation until PSA rises further if initial PSMA-PET is negative and risk features are truly favorable.

PSA 0.2–0.5 ng/mL, or moderately unfavorable features: Salvage radiotherapy to the prostate bed remains the standard. Adding 6 months of ADT and expanding the radiation field to cover pelvic nodes (WPRT) has been shown to meaningfully improve freedom from progression and metastasis-free survival in both SPPORT and GETUG-AFU 16.

PSA >0.5 ng/mL or high-risk features (short doubling time, high grade): More intensive treatment is warranted. Longer-duration ADT (24 months, per RADICALS-HD data) may be appropriate, particularly without pelvic nodal irradiation. For those not proceeding to salvage radiation, EMBARK data support enzalutamide plus leuprolide as a survival-improving systemic option.

The 2024 AUA/ASTRO/SUO joint guidelines emphasize that multidisciplinary discussion is essential when considering treatment intensification beyond prostate-bed radiation. No single algorithm fits every patient.

What About Watching and Waiting When PSMA-PET Is Negative?

A multicenter retrospective study published in early 2026 examined 89 patients with BCR and negative PSMA-PET who were managed with observation rather than immediate treatment. Among lower-risk patients, radiological progression occurred in 33%; among higher-risk patients, 55% progressed radiologically during follow-up. The study concluded that some selected low-risk patients may be safely observed, but higher-risk patients appear to benefit from earlier salvage radiotherapy even when no disease is visible on PSMA-PET.

Multiple other studies have reached similar conclusions: PSMA-PET outcome and SRT outcome are not strongly linked at low PSA levels. Patients with negative scans who receive SRT have similar biochemical recurrence-free survival rates to those with positive scans, suggesting that whatever micro-disease is driving the PSA rise is being addressed by the radiation even when it cannot be seen.

Testosterone-Sparing and Quality-of-Life Considerations

ADT has real costs: fatigue, loss of libido, hot flashes, bone density loss, metabolic effects, and mood changes. For many men, these side effects significantly affect quality of life. A growing body of research is examining "testosterone-sparing" approaches — ways to achieve good cancer control while minimizing hormonal side effects.

The EMBARK trial specifically allowed patients to suspend treatment at week 37 if PSA became undetectable, restarting only when PSA rose again. This intermittent approach helped manage the burden of continuous ADT. Enzalutamide monotherapy (without testosterone suppression) is another option that some patients with high-risk BCR may choose after discussion of the tradeoffs, given that it improved metastasis-free survival even though its overall survival benefit in EMBARK was not statistically superior to leuprolide alone.

Patients should feel empowered to ask their oncology team specifically about quality-of-life tradeoffs when any intensified treatment approach is proposed.

PSMA-Guided Dose Escalation: An Emerging Strategy

For patients whose PSMA-PET does show local or nodal disease, there is growing interest in using those findings to guide "dose escalation" — delivering extra radiation to the specific visible lesions, in addition to the standard prostate-bed field. The EMPIRE-2 trial and several meta-analyses published in 2025 and 2026 have evaluated this strategy. Early data suggest that PSMA-guided boosting of visible disease may improve local control, though longer follow-up is needed to confirm survival benefits.

The PSMAiSRT trial from Canada found that a substantial fraction of patients had their treatment plan modified based on PSMA findings: 23% received a prostate-bed boost and 30% received a nodal boost. Whether these modifications translate to survival improvements awaits longer follow-up, as the trial noted wide confidence intervals on early outcome estimates.

What Should Patients Do Now?

If you have had a radical prostatectomy and your PSA has risen, the most important first step is a thorough conversation with your urologic oncologist and radiation oncologist — ideally in a multidisciplinary team setting. Key questions to explore:

• What is my PSA doubling time, and what does that tell us about risk?
• Should I have a PSMA-PET scan, and how will the result change my treatment plan?
• Am I a candidate for prostate-bed radiation alone, or does my risk profile support adding pelvic nodal irradiation?
• What are the benefits and side effects of adding short-term versus long-term ADT to my radiation plan?
• Is my BCR high-risk enough to consider enzalutamide plus ADT (the EMBARK regimen)?
• What clinical trials are currently open for patients in my situation?

Remember: BCR is not the end of the road. Most men with BCR after radical prostatectomy have years of good quality life ahead. Many are cured by salvage radiotherapy. The field is advancing rapidly, with multiple new treatment options now proven to improve outcomes. Stay informed, stay engaged with your medical team, and don’t hesitate to seek a second opinion at a high-volume center.

Summary of Key Take-Home Points

• BCR affects up to half of all men within 10 years of prostatectomy but is not synonymous with incurable disease.
• Earlier salvage radiotherapy (at lower PSA levels) consistently produces better outcomes.
• PSMA-PET is the best available imaging tool but detects disease in fewer than half of patients at the low PSA levels where early salvage treatment is recommended. A negative scan should not delay treatment.
• Adding whole-pelvis radiation and 6 months of ADT to salvage RT improves outcomes for most patients, including those with PSA below 0.5 ng/mL (SPPORT, GETUG-AFU 16).
• Longer ADT (24 months) benefits patients who receive prostate-bed radiation without pelvic coverage, particularly those with higher PSA at recurrence (RADICALS-HD).
• For high-risk BCR not managed with salvage radiation, enzalutamide plus leuprolide now has proven overall survival benefit (EMBARK 2025).
• Treatment decisions should be individualized through multidisciplinary discussion, weighing cancer control, side effects, and patient preferences.

Verified Sources and Formal Citations

1. D’Angelillo RM, Trodella LE, Fiore M, Ippolito E, Greco C, Ramella S. “Biochemical recurrence after radical prostatectomy: Where do we stand to?” Prostate Cancer and Prostatic Diseases. 2026. doi: 10.1038/s41391-026-01125-4
2. Shore ND, Luz MA, De Giorgi U, et al. “Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer.” New England Journal of Medicine. 2026;394:563–575. doi: 10.1056/NEJMoa2510310
3. Pollack A, Karrison TG, Balogh AG, et al. “The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.” Lancet. 2022;399:1886–1901. doi: 10.1016/S0140-6736(21)01790-6
4. Carrie C, Magné N, Burban-Provost P, et al. “Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3 randomised trial.” Lancet Oncology. 2019;20:1740–1749. doi: 10.1016/S1470-2045(19)30662-1
5. Parker CC, Clarke NW, Cook AD, et al. “Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.” Lancet. 2024;403:2405–2415. doi: 10.1016/S0140-6736(24)00163-4
6. Parker CC, Kynaston H, Cook AD, et al. “Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial.” Lancet. 2024;403:2416–2425. doi: 10.1016/S0140-6736(24)00164-6
7. Kishan AU, Sun Y, Parker CC, et al. “Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis (POSEIDON).” Lancet. 2026;407:1059–1071. doi: 10.1016/S0140-6736(25)02645-4
8. Burdett S, Fisher DJ, Tierney JF, et al. “Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate Data.” European Urology. 2025;88:277–290. doi: 10.1016/j.eururo.2025.04.012
9. Belliveau C, Saad F, Duplan D, et al. “Prostate-Specific Membrane Antigen PET-Guided Intensification of Salvage Radiotherapy After Radical Prostatectomy: A Phase 2 Randomized Clinical Trial (PSMAiSRT).” JAMA Oncology. 2025;11:1431–1438. doi: 10.1001/jamaoncol.2025.1955
10. Nikitas J, Smith CP, Armstrong WR, et al. “Five-year outcomes after prostate-specific membrane antigen PET/CT-guided salvage radiotherapy following radical prostatectomy.” Journal of the National Comprehensive Cancer Network. 2026;24(2):11–18. doi: 10.6004/jnccn.2025.7102. See also: Urology Times summary
11. Observational Management for Patients with BCR Following Radical Prostatectomy, in the Absence of Detectable Disease on Restaging PSMA PET/CT Imaging. MDPI/PMC. Published January 2026. PMC full text
12. Migliaccio F, Flauto F, Barraco C, et al. “Salvage radiotherapy with or without hormonal therapy for biochemical recurrence after radical prostatectomy: A systematic review and meta-analysis.” Prostate Cancer and Prostatic Diseases. May 2026. doi: 10.1038/s41391-026-01120-9
13. Makedon AM, Morgan TM. “New AUA/ASTRO/SUO Prostate Cancer Salvage Therapy Guidelines.” AUA News. January 2025. AUA News link
14. AUA/ASTRO/SUO Salvage Therapy for Prostate Cancer Guidelines, Parts I, II, and III. Journal of Urology. 2024. Part I: doi link; Part II: doi link
15. Sayyid RK, Lee DI, Dobbs RW, Shahait M. “Testosterone-Sparing Treatment Strategies for Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.” Current Oncology Reports. 2026;28(1). doi: 10.1007/s11912-026-01776-5
16. EMBARK trial summary and OS results: CancerNetwork report (October 2025). CancerNetwork article; UroToday ESMO 2025 report: UroToday link
17. European Association of Urology. EAU Guidelines on Prostate Cancer (2026 edition). uroweb.org/guidelines/prostate-cancer
18. Shore ND, Moul JW, Pienta KJ, et al. “Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification.” Prostate Cancer and Prostatic Diseases. 2024;27:192–201. doi: 10.1038/s41391-023-00754-z

This article was prepared for educational purposes for members and supporters of the Informed Prostate Cancer Support Group (IPCSG). It is not intended as personal medical advice. Please consult your oncology team before making any changes to your care plan. IPCSG encourages all patients to bring new research to their physician’s attention and to participate in clinical trials where eligible.

© 2026 IPCSG Educational Newsletter. May be reproduced for non-commercial patient education with attribution.